Myosin Therapeutics Awarded $3 Million NIH Grant To Advance Clinical Trial for MT-110 in Methamphetamine Use Disorder
UF Startup Myosin Therapeutics, Inc., a biotechnology company developing innovative therapies for cancer and neurological disorders, announced that it has been awarded a $3 million grant from NIDA, part of NIH.
